ELI LILLY & CO (LLY)
US5324571083 - Common Stock
ELI LILLY & CO
NYSE:LLY (7/25/2024, 7:04:00 PM)
After market: 817.5 -3.69 (-0.45%)821.19
-38.69 (-4.5%)
Company Profile
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 43,000 full-time employees. The firm discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The firm manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.
Company Info
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr
Indianapolis INDIANA 46285
P: 13172762000
CEO: David A. Ricks
Employees: 43000
Website: https://www.lilly.com/
LLY News
4 hours ago - The Motley FoolWhy Weight Loss Drug Developer Stocks Tumbled on ThursdayCompanies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category.
4 hours ago - Yahoo FinanceWhy Weight Loss Drug Developer Stocks Tumbled on ThursdayCompanies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category.
5 hours ago - InvestorPlace7 Explosive Growth Stocks Set to Soar in 2024These seven explosive growth stocks across various sectors have the potential to deliver substantial returns for investors in 2024.
6 hours ago - Yahoo FinanceLilly Loses $120 Billion in Value as Rival Obesity Drugs Impress(Bloomberg) -- Eli Lilly & Co. is down more than $120 billion in market value and its status as the poster child of the weight-loss drug frenzy is under threat with at least two rivals posting encouraging developments for their obesity treatments.Most Read from BloombergTrump Risks Losing Voters He Needs With Loaded Attacks on HarrisHarris Just Showed Why Trump Is So Afraid of HerMarkets Tear Up Popular Trades That Reached ‘Stupid Levels’Stocks Caught in Tug of War Between Tech and Rest: Markets
8 hours ago - InvestorPlace3 Top-Performing Stocks Beating the Big Names in 2024The following top-performing stocks may continue to gain as the Magnificent Seven runs out of steam in July.
8 hours ago - BloombergLilly Loses $120 Billion in Value as Rival Obesity Drugs ImpressEli Lilly & Co. is down more than $120 billion in market value and its status as the poster child of the weight-loss drug frenzy is under threat with at least two rivals posting encouraging developments for their obesity treatments.
LLY Twits
Here you can normally see the latest stock twits on LLY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
